US5545409A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Delivery system for controlled release of bioactive factors
Assignee: Massachusetts Institute of Technology
•
Filing: 1994-04-05
•
Granted: 1996-08-13
•
Expires: 2014-04-05
Abstract
Abstract A composition and method for controlled release of water-soluble proteins comprising a surface-eroding polymer matrix and water-soluble bioactive factors is described. The composition bioerodes in the biological environment of the subject at a controlled rate, thereby releasing the water soluble proteins at a rate which allows them to interact with local cell populations.
Inventors
- 👤 Cato T. Laurencin
- 👤 Paul A. Lucas
- 👤 Glenn T. Syftestad
- 👤 Abraham Domb
- 👤 Julianne Glowacki
- 👤 Robert S. Langer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 23:16
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204; A61L; A61L27/00; A61L27/14; A61L27/18; A61L27/22; A61L27/227; A61L27/50; A61L27/54; A61L27/58; C; C08; C08G; C08G67/00; C08G67/04; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/60; A61L2300/602; A61L2300/604; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/84
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
141 words
A composition for the controlled release of a bioactive substance for inducing formation of cartilage or bone in an animal or wound healing comprising: a. a shaped matrix sized and adapted for administration of the bioactive substance to an animal and formed of a polymer selected from the group consisting of polyanhydride and polyorthoester; and b. a therapeutically effective amount of a bioactive substance selected from the group consisting of water soluble chondrogenic or osteogenic proteins derived from demineralized bone matrix, TGF-beta, EGF, FGF and PDGF, wherein the bioactive substance is present in an amount of between about 10 and 90 percent by weight of matrix; wherein the composition erodes at a controlled rate over a period of time, thereby administering the bioactive substance to the animal in an amount effective to induce formation of cartilage and bone or wound healing.
Claim 2
Dependent Claim
141 words
A composition for the controlled release of a bioactive substance for inducing formation of cartilage or bone in an animal or wound healing comprising: a. a shaped matrix sized and adapted for administration of the bioactive substance to an animal and formed of a polymer selected from the group consisting of polyanhydride and polyorthoester; and b. a therapeutically effective amount of a bioactive substance selected from the group consisting of water soluble chondrogenic or osteogenic proteins derived from demineralized bone matrix, TGF-beta, EGF, FGF and PDGF, wherein the bioactive substance is present in an amount of between about 10 and 90 percent by weight of matrix; wherein the composition erodes at a controlled rate over a period of time, thereby administering the bioactive substance to the animal in an amount effective to induce formation of cartilage and bone or wound healing.
Claim 3
Dependent Claim
24 words
The composition of claim 1 wherein the polyanhydride is selected from the group consisting of: poly[bis(p-carboxyphenoxy)propane anhydride], poly[bis(p-carboxy)methane anhydride] and poly[bis)p-carboxyphenoxy)propane anhydride]--sebacid acid copolymer.
Claim 4
Dependent Claim
25 words
The composition of claim 1 wherein the water soluble chondrogenic or osteogenic proteins derived from demineralized bone matrix is a mixture of cold water-soluble proteins.
Claim 5
Dependent Claim
17 words
The composition of claim 3 wherein the cold water-soluble proteins are proteins derived from demineralized bone matrix.
Claim 6
Dependent Claim
19 words
The composition of claim 1 wherein the chondrogenic or osteogenic proteins is derived from demineralized bovine femur bone matrix.
Claim 7
Dependent Claim
22 words
The composition of claim 1 where in the bioactive substance is selected from the group consisting of TGF-beta, EGF, FGF and PDGF.
Claim 8
Dependent Claim
18 words
The composition of claim 1 wherein the composition comprises a continuous matrix having a bioactive substance interspersed therethrough.
Claim 9
Dependent Claim
18 words
The composition of claim 1 wherein the matrix is sized, shaped and adapted for use as an implant.
Claim 10
Dependent Claim
13 words
The composition of claim 1 which is adapted for releasing bioactive substance intramuscularly.
Claim 11
Dependent Claim
85 words
The composition of claim 1 wherein the shaped matrix sized and adapted for administration of the cartilage and bone inducing substance is formed from a polyanhydride polymer selected from the group consisting of poly(bis(p-carboxyphenoxy)propane anhydride), poly(bis(p-carboxyphenoxy)methane anhydride) and poly(bis(p-carboxyphenoxy)propane anhydride-sebacic acid); and the cartilage and bone inducing amount of a protein preparation derived from demineralized bone matrix consists of a mixture of cold water-soluble proteins capable of inducing chondrogenesis and osteogenesis having a range of molecular weight of from about 10 to about 100 Kd.
References Cited (Backward Citations)
CA684685A
Cited
US2072250A
Cited
US2071251A
Cited
US2073799A
Cited
US2621145A
Cited
US2676945A
Cited
US2668162A
Cited
US2958678A
Cited
GB840846A
Cited
GB840847A
Cited
US2960493A
Cited
GB838986A
Cited
GB968715A
Cited
US3887699A
Cited
US4419340A
Cited
US3526612A
Cited
US3625214A
Cited
US3766145A
Cited
US3960150A
Cited
US3981303A
Cited
US3986510A
Cited
US3993071A
Cited
US3914401A
Cited
US3811444A
Cited
US4036227A
Cited
US3991766A
Cited
US3976071A
Cited
US4014987A
Cited
US4096238A
Cited
US4070347A
Cited
US4675189A
Cited
US4610692A
Cited
US4394370A
Cited
US4489056A
Cited
US5328695A
Cited
US5286763A
Cited
US4906474A
Cited
JPS60141725A
Cited
US4563489A
Cited
US4609551A
Cited
US4886870A
Cited
US4891225A
Cited
US4888176A
Cited
US4612009A
Cited
US4637931A
Cited
US4797282A
Cited
FR2590262A1
Cited
US4806621A
Cited
US4832686A
Cited
US4757128A
Cited
US4789724A
Cited
US5013553A
Cited
WO1989000855A1
Cited
US4961707A
Cited
US4975526A
Cited
US5122367A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-08-13 | 2000-02-12 | 2000-08-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-08-13 | 2004-02-12 | 2004-08-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-08-13 | 2008-02-12 | 2008-08-13 | $7700.00 | Window Closed / Lapsed |